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therapy and radiation are irreversible, and for pediatric
cancer patients oral sequelae and discomfort related to
their treatment can have long-term consequences.
Conditioning for stem cell transplantation (SCT) has
been shown to cause more severe disturbances
compared to most chemotherapy protocols [1]. On
the other hand, efforts that have been made to reduce
the intensity of conditioning, for example, use of
busulfan for total-body irradiation (TBI) will reduce
the prevalence of salivary dysfunction, and dose frac-
tionation of TBI will result in less salivary dysfunction
as well as less dental developmental disturbances.
Knowledge of the oral and dental late effects is impor-
tant because many children are affected and there often
is a need for early intervention. This review will focus
on the increased risk of developing dental caries,
salivary dysfunction, and developmental changes,
including damage to developing teeth.
An evaluation of oral health is a part of the prepara-
tion for stem cell transplantation in many centers. This
is warranted, because many children have preexisting
oral diseases. In a group of 259 children preparing for
SCT, oral diseases were diagnosed in 58% [2].
DENTAL CARIES
Studies with longer follow-up time have shown an
increased risk for dental caries among long-term survi-
vors after childhood cancer. One study particularly
pointed out the period of induction therapy as a period
of increased caries risk. Three particular risk factors
can be identified: radiation therapy, including salivary
glands, for example TBI [3], if the child has high caries
prevalence at the start of cancer therapy [4], and lack of
caries preventive care during the first year of cancer
treatment [5].
We have preliminary data from a nationwide
population-based study linking records from the Dan-
ish Cancer Registry with records from the nationaldatabase on oral health. The study included 7-, 12-
and 15-year-old children. Those whose dental exami-
nation had been preceded by a cancer diagnosis were
compared with children without a cancer diagnosis.
Children diagnosed with cancer before the age of 5
years did not have increased caries prevalence in
permanent teeth at age 12. Children diagnosed with
cancer between 5 and 6 years of age had an increased
prevalence of caries in smooth tooth surface at age 12
years (prevalance rate [PR] 5 1.59; 95% confidence
interval [CI]: 1.09-2.31). For children diagnosed with
cancer at 5 or 6 years of age and who received radiation
therapy the PR of caries in 1 or more smooth tooth
surface was significantly increased. We investigated 2
cohorts of children with cancer: those born between
1993 and 1997 had a lower prevalence of dental caries
than those children with cancer born 1984-1988. This
may be the result from development of targeted dental
treatment procedures and oral hygiene guidelines for
children undergoing cancer therapy during the early
1990s. Our results indicate an increased caries risk in
children 5 or 6 years at diagnosis, those treated with ra-
diation therapy, and a decreasing trend of dental caries
in children with cancer [6].
There are effective programs for caries prevention
based on the use of fluorides, antibacterial substances
such as chlorhexidine, and effective plaque control
[7]. Recent developments that will be commercially
available are fluoride slow release devices that do not
require patient involvement except for periodic
replacement, thus reducing the effect of patient
compliance [8].
SALIVARY DYSFUNCTION
Children conditioned with TBI are at risk to
develop salivary dysfunction [9]. Children conditioned
with single-dose TBI will have a permanently damaged
salivary secretion rate. Many of the long-term survivors
will have stimulated salivary secretion rated below81
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for dental caries. We also have preliminary data from
a comparison of long-term survivors conditioned with
10 Gy single-dose TBI to those conditioned with 3 
4 Gy fractionated TBI (fTBI). The results show that
at the 1-year follow-up children treated with fTBI
had a stimulated salivary secretion rate. Children
treated with fTBI had a secretion rate of 1.0 6 0.5
mL/min, a 10% reduction compared to baseline; the
TBI-group had 0.5 6 0.3 mL/min, a 54% reduction
(P \ .001). The unstimulated salivary secretion rate
in the fTBI group was 0.4 6 0.3 mL/min, a 13%
reduction compared to baseline, and in the TBI group,
0.1 6 0.1 mL/min, a 66% reduction (P 5 .0011). The
incidence of chronic graft-versus-host was similar in
the 2 groups, and did not affect the salivary secretion
rate. One particular aspect of salivary dysfunction in
children is that they rarely complain about mouth
dryness, even though they objectively have a very low
salivary output. An interview that focuses on everyday
situations may reveal signs and symptoms of mouth
dryness. We investigated 53 children surviving more
than 2 years. Salivary gland dysfunction was present
in 35% of the patients. Seventy-nine percent of the
patients expressed 1 or more symptom of dry mouth,
and 49% gave at least 2 answers indicating dry mouth.
The number of complaints increased with age at exam-
ination (P\ .05). A reduction in stimulated salivary
secretion rate compared with the year before was corre-
lated to 2 or more complaints of xerostomia (P\ .01).
The presence of dry mouth at night or on awakening
was indicative of both low salivary function (P \
.001). In contrast to the situation in adults, there is
a correlation between the expression of subjective
complaints of xerostomia and salivary gland dysfunc-
tion in children [10].
DISTURBANCES IN DENTAL DEVELOPMENT
Disturbances in dental development and particu-
larly in root development after cancer therapy is
characterized by arrested root development with short
V-shaped roots, arrested root development with
premature apical closure, microdontia, and also an
increased incidence of aplasia. Children subjected to
radiation therapy at an early age are particularly at
risk. In a comparison between children treated with
chemotherapy protocols for malignant diseases and
children conditioned with 10 Gy of TBI before SCT,
Na¨sman et al [11] found a mean number of 4.1 6 5.0
teeth were affected by disturbances in enamel mineral-
ization. In the TBI group, 4.6 6 4.6 teeth were
affected, both significantly higher compared with the
healthy control group 0.7 6 1.4 (P \ .05). White/
cream-colored opacities were most commonly diag-
nosed in all 3 groups, followed by yellow/brown
opacities. Twelve percent of the children treatedwith TBI and 8% treated with chemotherapy exhibited
hypoplasia. In a study of children with poor-risk
neuroblastoma treated with high-dose chemotherapy
and autologous SCT with or without TBI before 5.8
years of age, all children had disturbances in dental de-
velopment. Children in the TBI group had 2 to 12
missing permanent teeth (mean 5 6.6), and 27% of
all permanent teeth were missing. In those not treated
with TBI, 4.8% of the teeth were missing.
A combination of busulfan (BU) with a lower dose of
cyclophosphamide (CY) has been used in different types
of leukemia and other diseases with acceptable levels of
toxicity. We have preliminary data from a comparison
of the effect of BU (16 mg/kg) and CY (120 mg/kg)
and TBI 10 Gy single dose and CY (120 mg/kg) on den-
tal development. Eighty-one recipients of allogeneic
SCT were studied. The mean age in the TBI/CY group
was 8.5 6 4.2, and in the BU/CY group, 6.1 6 4.0.
Adjusted for the age difference children conditioned
with BU/CY had significantly more aplasia (including
third molar) and teeth reduced in size compared those
conditioned with single-dose TBI (Figure 1). Prelimi-
nary data reveal, on the other hand, that the children
conditioned with BU/CY had a significantly better
salivary secretion rate 1 year after SCT compared to
those conditioned with TBI/CY (Figure 1).
Children who are long-term survivors after SCT
may require orthodontic treatment because of differ-
ent types of malocclusions [12]. The treatment may
be complicated because of disturbances in dental
development, particularly in the root development.
We have studied the course of treatment in 10 children
and not found an increased risk of complications
because of the orthodontic treatment. Treatment start
should be postponed until 2 years after completion of
cancer therapy [13].
In conclusion, this review shows that with reduced
intensity conditioning the prevalence of oral and
dental late effects will be less severe in the future.
Figure 1. Panoramic radiograph at 9 years showing the dentition of
a 9-year old boy with MDS conditioned with BU/CY for SCT at 7
months of age. Severe disturbances of development of dentition
and alveolar processes can be seen. Eighteen of 32 permanent teeth
are missing. Enamel hypoplasia as well as disturbances in root devel-
opment can be seen on all first permanent molars. The roots of the
primary teeth are all resorbed.
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of salivary glands. Many children preparing for SCT
have preexisting oral diseases and those with high car-
ies prevalence at risk to develop new lesions. In chil-
dren subjected to TBI there is a strong correlation
between xerostomia (the subjective feeling) and
a reduced salivary secretion rate. Children should be
asked specific questions regarding the subjective
feeling of xerostomia.
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